'I am thrilled to have joined
OncoCyte at such a pivotal time in the company's evolution,' said Ron Andrews, Chief Executive Officer of
OncoCyte.
Biotechnology company BioTime Inc (NYSE American and TASE:BTX) said on Tuesday that it has priced the sale of 2,250,000 common stock of
OncoCyte Corporation at a price of USD2.00 per share.
Various glandular and secretory epithelia show
oncocytes. Most of the oncocytic lesions are benign with a relatively low rate of proliferation.
*
OncoCyte Corporation (NYSE:OCX) surged 12.9% to close at $2.27.
DOWN AFTER EARNINGS:
OncoCyte Corporation (OCX) down 15.3%...
Acquiring Asterias, distributing AgeX, reducing our
OncoCyte ownership, hiring a new management team, reducing overhead and headcount, and relocating clinical operations for our OpRegen program to the U.S.
(USCN) of Wuhan, China, granting BioTime an option to license USCN's antibody-producing cell lines and certain related technology that may be used by BioTime and its subsidiary
OncoCyte Corporation for the large-scale manufacture of the antibody components of PanC-Dx.
As part of the transaction, BioTime will acquire a phage display peptide technology which the purchaser will then provide to its
OncoCyte unit, established to develop genetically modified stem cells used to destroy cancer cells.Country: , USASector: BiotechnologyTarget: Cell Targeting IncBuyer: BioTime IncDeal size in USD: 250,000Type: Corporate acquisitionFinancing: Cash & StockStatus: ClosedComment: Deal size refers to cash portion only.
Benchmark analyst Bruce Jackson said that he views yesterday's price action in shares of
OncoCyte after the company announced that it needs additional time to complete the CLIA validation study as overdone.
Diagnostic tests company BioTime (NYSE MKT:BTX) (TASE:BTX) reported on Monday the addition of Cavan Redmond as an independent member of the board of directors of its subsidiary
OncoCyte.
3 October 2014 - US biotech group BioTime Inc (NYSEAMEX:BTX) and its unit
OncoCyte Corporation said Friday that
OncoCyte's partner, The Wistar Institute, had finalise recruitment of a large, multi-site trial assessing a blood-based lung cancer diagnostic test.
"BioTime's HyStem product line is one of four components in our near-term revenue strategy, which also includes Hextend revenues, sales of stem cell research products (including the ACTCellerate cell lines and associated products), and planned near-term products being developed by our subsidiary
OncoCyte Corporation," said CEO Michael West.
